FDA’s Real-Time Clinical Trial Push: Industry Information Session on Real-Time Clinical Trials Request for Information (RFI)
On April 28, 2026, the Food and Drug Administration (FDA) announced a shift in how clinical development may be conducted and reviewed for real-time clinical trials (RTCT). The Agency launched two early proof-of-concept clinical trials that will report certain safety signals and study results to the FDA in real time. The FDA also asked for feedback, i.e., “Request for Information (RFI)” on a broader pilot program that is expected to begin this summer [1] . The FDA wants to see important trial data as it happens instead of waiting months or even years for formal updates. The idea is to speed up learning, spot problems earlier, and potentially move promising treatments through development faster.
Today, clinical trials usually follow a longer chain of events such as study sites collecting data, the drug company/manufacturer reviewing it, and then the FDA reviewing it later through formal submissions. This process can create long delays, especially in early-stage trials where every decision matters. The FDA’s new approach aims to cut that lag. If regulators can review agreed upon signals in real-time, they may be able to identify safety issues sooner and make decisions faster. The Agency has said this could support a future with more “continuous” trials, where there is less downtime between one phase of development and the next.
What does this mean for manufacturers? Those closest to the clinical trial process, such as drug manufacturers, are the most impacted. This change is both exciting and demanding. On the positive side, real-time trials could help companies make faster decisions, reduce avoidable delays, and get better feedback from regulators while a study is still underway. This update could be valuable in areas like cancer or rare diseases where patient populations are small and time is critical. On the other hand, companies would need stronger systems behind the scenes. They must be able to collect the right data quickly, clean it, validate it, protect patient privacy, and share it securely. In other words, this is not just a new reporting method; it may require companies to rethink how they run trials, manage vendors, and coordinate teams across clinical, regulatory, safety, data, and technology functions.
The concept is promising but success will depend on trust in the data and clear operating rules. Some key areas for consideration include, but are not limited to:
Applicability: not every trial will be a good fit for real-time reporting. Companies will need to know exactly which data should be shared, how it will be checked, and how often regulators may respond.
Balancing: faster updates are helpful, but they should not create confusion or lead to rushed decisions.
Artificial Intelligence (A.I.): patient privacy, data security, and clear rules for how A.I. tools are used will be critical.
The FDA has currently opened its comments on the Request for Information. Electronic or written comments must be received by June 29, 2026, as the final pilot selection criteria will be disseminated in July 2026 and the complete pilot selections in August 2026. This timeline means manufacturers should already be looking at their systems, trial processes, and external partners to ensure all are ready for a faster, more connected model. Even companies that do not join the pilot right away may feel pressure to modernize if the program moves forward and competitors begin to benefit from faster development cycles.
The bottom line: the FDA’s announcement is a sign that drug development may be entering a more real-time era. If this approach works, it could help bring promising therapies to patients faster by cutting some of the delay built into today’s trial process. For manufacturers, finding resources and combining speed with strong data systems, careful oversight, and patient protection, is a great opportunity but is also challenging. Real-time clinical trials are not just a new FDA pilot; they could become an early preview of how the next generation of clinical development will work.
Thanks for joining us! Keep checking back as we continue following industry trends!
Have any questions? Contact us here!
Reference